Bigul

THEMIS MEDICARE LTD. - 530199 - Board Meeting Intimation for Inter Alia, To Consider, The Un-Audited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended On 31St December, 2022.

THEMIS MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 ,inter alia, to consider and approve With respect to the captioned subject, please be informed that a meeting of the Board of Directors of Themis Medicare Limited is scheduled to be held on Friday 03rd February, 2023 inter alia, to consider, the Un-audited Standalone and Consolidated Financial Results for the Quarter and nine months ended on 31st December, 2022. Further, in continuation of our Letter dated 26th December 2022, the Trading Window in respect of dealing in the Company's Securities was closed for all Directors/Designated Employees from the opening of the trading hours on Sunday, 1st January, 2023, which shall remain closed till the closure of trading hours on 05th February, 2023 (both days inclusive) i.e. till the completion of 48 hours after the declaration of financial results as per the policy for prohibition of Insider Trading ("the Code") adopted by the Company pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time.
27-01-2023
Bigul

THEMIS MEDICARE LTD. - 530199 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

This is to inform that the Company has allotted 2500 (two thousand five hundred only) Equity shares of Rs.10/-(Rupees Ten only) each on January 27, 2023 to those grantees who had exercised their option under the Company's Employee Stock Option Scheme. The said shares will rank pari-passu with the existing shares of the Company in all respect. Please take the above on record and upload this announcement on the website of the Exchange.
27-01-2023
Bigul

THEMIS MEDICARE LTD. - 530199 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

We are enclosing herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2022 received from Link lntime India Pvt. Ltd., Registrar and Share Transfer Agent of our Company. This is for your information and record.
11-01-2023
Bigul

THEMIS MEDICARE LTD. - 530199 - Scrutinizer Report And Voting Result

Pursuant to Regulation 44(3) of the SEBI (LODR) Regulations, 2015, we are enclosing herewith the Report submitted by the Scrutinizer CS Shirish Shetye(FCS 1926), Designated Partner of M/s. SAV & Associates LLP, Practicing Company Secretaries, Mumbai, along with the voting results, with respect to Postal Ballot/ electronic voting (e-voting) conducted by the Company for seeking approval of members by way of Special Resolution for the sale / transfer of the Company's API business to Themis Lifestyle Private Limited a subsidiary of the Company in the prescribed format for your information and record. The same is also uploaded on the Company''s website at: www.themismedicare.com.
10-01-2023
Bigul

THEMIS MEDICARE LTD. - 530199 - Scrutinizer Report And Voting Result

Pursuant to Regulation 44(3) of the SEBI (LODR) Regulations, 2015, we are enclosing herewith the Report submitted by the Scrutinizer CS Shirish Shetye(FCS 1926), Designated Partner of M/s. SAV & Associates LLP, Practicing Company Secretaries, Mumbai, along with the voting results, with respect to Postal Ballot/ electronic voting (e-voting) conducted by the Company for seeking approval of members by way of Special Resolution for the sale / transfer of the Company's API business to Themis Lifestyle Private Limited a subsidiary of the Company in the prescribed format for your information and record. The same is also uploaded on the Company''s website at: www.themismedicare.com.
10-01-2023
Bigul

THEMIS MEDICARE LTD. - 530199 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Pursuant to Regulation 39(3) of the SEBI (LODR) Regulation, 2015, we would like to inform you that the Registrar and Transfer Agent of the Company i.e. Link Intime India Private Limited has received the below mentioned intimation / request for Loss of Share Certificate / issuance of duplicate share certificate from the following shareholder mentioned in the attached file.
05-01-2023
Bigul

THEMIS MEDICARE LTD. - 530199 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

In terms of Regulation 30 of the SEBI (LODR) Regulations, 2015, we are enclosing herewith a copy of the press release titled - 'Themis Medicare Launches Lenzetto(r) - Global brand of Estradiol Novel Drug Delivery System for treatment of Menopausal symptoms'.
03-01-2023
Bigul

THEMIS MEDICARE LTD. - 530199 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Pursuant to Regulation 39(3) of the SEBI (LODR) Regulation, 2015, we would like to inform you that the Registrar and Transfer Agent of the Company i.e. Link Intime India Private Limited has received the below mentioned intimation / request for Loss of Share Certificate / issuance of duplicate share certificate from the following shareholder: Name Folio No. Cert. No. Number of Shares Dist. No. From Dist. No. To NIRMAL BANSAL 00007126 10989 100 3814801 3814900 We shall issue the duplicate Share Certificate only after the necessary formalities are carried out by the Shareholder. This may be taken as compliance under the Listing Regulations.
28-12-2022
Bigul

THEMIS MEDICARE LTD. - 530199 - Closure of Trading Window

We would like to inform you that as per the Company''s minimum Standards Code of Conduct to regulate, monitor and report trading by its Employees and other Connected Persons under SEBI (PIT) Regulations, 2015 (as amended) (PIT Regulations) and pursuant to BSE Circular Ref No: LIST/COMP /01/2019-20 dated 2nd April, 2019 and NSE Circular Ref No. NSE/CML/2019/11, the Trading Window for dealing in the Securities of the Company shall remain closed on and from 1st January, 2023 and will re-open after completion of 48 hours from the declaration of financial results for the quarter and nine months ended 31.12.2022 by the Board of Directors of the Company. The same has been intimated to all the directors, officers and designated employees of the Company. Further the date of Board Meeting for considering the said financial results for the quarter and nine months ended 31.12.2022 shall be intimated in due course. We request you to kindly take the above information on record.
26-12-2022
Bigul

THEMIS MEDICARE LTD. - 530199 - Closure of Trading Window

We would like to inform you that as per the Company''s minimum Standards Code of Conduct to regulate, monitor and report trading by its Employees and other Connected Persons under SEBI (PIT) Regulations, 2015 (as amended) (PIT Regulations) and pursuant to BSE Circular Ref No: LIST/COMP /01/2019-20 dated 2nd April, 2019 and NSE Circular Ref No. NSE/CML/2019/11, the Trading Window for dealing in the Securities of the Company shall remain closed on and from 1st January, 2023 and will re-open after completion of 48 hours from the declaration of financial results for the quarter and nine months ended 31.12.2022 by the Board of Directors of the Company. The same has been intimated to all the directors, officers and designated employees of the Company. Further the date of Board Meeting for considering the said financial results for the quarter and nine months ended 31.12.2022 shall be intimated in due course. We request you to kindly take the above information on record.
26-12-2022
Next Page
Close

Let's Open Free Demat Account